Network meta-analysis (NMA) of pembrolizumab for first-line (1L) treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

被引：0
|
作者：
Ramakrishnan, Karthik
Mojebi, Ali
Ayers, Dieter
Chirovsky, Diana Romana
Borse, Rebekah
Keeping, Sam
机构：
[1] Merck & Co Inc, Kenilworth, NJ USA
[2] PRECISIONheor, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18012
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Comparative efficacy of pembrolizumab with carboplatin and paclitaxel as first-line (1L) therapy in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A network meta-analysis (NMA) with matching-adjusted indirect comparison (MAIC).
    Zheng, Dandan
    Mojebi, Ali
    Black, Christopher M.
    Giezek, Hilde
    Naicker, Niroshini
    Vanetta, Chiara
    Keeping, Sam
    Merchant, Sanjay
    Dzienis, Marcin Radoslaw
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Cost-effectiveness (CE) analysis of pembrolizumab as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the United States (US).
    Ramakrishnan, Karthik
    Jain, Disha
    Gandhi, Jyotika
    Chirovsky, Diana Romana
    Borse, Rebekah
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.
    Fayette, Jerome
    Clatot, Florian
    Brana, Irene
    Saada, Esma
    van Herpen, Carla M. L. -
    Mazard, Thibault
    Perez, Cesar Augusto
    Tabernero, Josep
    Le Tourneau, Christophe
    Hollebecque, Antoine
    Arrula, Virginia Arrazubi
    Fontana, Elisa
    Kato, Shumei
    Sacco, Assuntina G.
    Harandi, Amir
    De Boer, J. P.
    Hellyer, Jessica
    Pennella, Eduardo
    Joe, Andrew K.
    Daste, Amaury
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Comparative Efficacy of KEYNOTE-B10 Regimen as First-Line (1L) Therapy in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): A Network Meta-Analysis (NMA) with Aggregate-Level Matching
    Zheng, D.
    Black, C. M.
    Mojebi, A.
    Keeping, S.
    Park, J. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E32 - E33
  • [5] REAL-WORLD OVERALL SURVIVAL AMONG PATIENTS RECEIVING FIRST-LINE (1L) PEMBROLIZUMAB IN THE TREATMENT OF RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) IN THE UNITED STATES
    Black, Christopher
    Wang, Liya
    Ramakrishnan, Karthik
    Hair, Gleicy
    Goto, Daisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A831 - A831
  • [6] Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis
    Xiao Yu
    Xiaolei Su
    Ling Fang
    Honglei Zhang
    Xi Chen
    Yu Pu
    Hongyi Liu
    Rui Guo
    European Archives of Oto-Rhino-Laryngology, 2023, 280 : 1391 - 1401
  • [7] Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis
    Yu, Xiao
    Su, Xiaolei
    Fang, Ling
    Zhang, Honglei
    Chen, Xi
    Pu, Yu
    Liu, Hongyi
    Guo, Rui
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2023, 280 (03) : 1391 - 1401
  • [8] KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
    Burtness, B.
    Harrington, K. J.
    Greil, R.
    Soulieres, D.
    Tahara, M.
    De Castro, G., Jr.
    Psyrri, A.
    Rotllan, N. Baste
    Neupane, P. C.
    Bratland, A.
    Fuereder, T.
    Hughes, B. G. M.
    Mesia, R.
    Ngamphaiboon, N.
    Rordorf, T.
    Ishak, W. Z. Wan
    Roy, A.
    Cheng, J.
    Jin, F.
    Rischin, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] REAL-WORLD TREATMENT PATTERNS AND SURVIVAL WITH FIRST-LINE (1L) PEMBROLIZUMAB plus PLATINUM plus TAXANE THERAPY FOR PATIENTS WITH RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) IN THE UNITED STATES
    Black, C.
    Hanna, G. J.
    Wang, L.
    Ramakrishnan, K.
    Hair, G.
    Zheng, D.
    Goto, D.
    VALUE IN HEALTH, 2023, 26 (06) : S18 - S18
  • [10] REAL WORLD TREATMENT PATTERNS FOR FIRST LINE (1L) RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) PATIENTS
    Contente, M.
    Mtibaa, M.
    Hall, J.
    Bailey, H.
    Bailey, A.
    Di Rienzo, P.
    Polanco, C.
    Singh, P.
    VALUE IN HEALTH, 2019, 22 : S108 - S109
12345